DIAMOND BIOFUND INC
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.
DIAMOND BIOFUND INC (6901) - Total Liabilities
Latest total liabilities as of September 2025: NT$168.32 Million TWD
Based on the latest financial reports, DIAMOND BIOFUND INC (6901) has total liabilities worth NT$168.32 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DIAMOND BIOFUND INC - Total Liabilities Trend (2019–2024)
This chart illustrates how DIAMOND BIOFUND INC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
DIAMOND BIOFUND INC Competitors by Total Liabilities
The table below lists competitors of DIAMOND BIOFUND INC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hana Technology Co. Ltd
KQ:299030
|
Korea | ₩146.39 Billion |
|
Figeac Aero SA
PA:FGA
|
France | €619.70 Million |
|
Bonduelle S.C.A.
PA:BON
|
France | €1.38 Billion |
|
Shanghai Broadband Technology Co Ltd
SHG:600608
|
China | CN¥78.63 Million |
|
Taiyen Biotech Co Ltd
TW:1737
|
Taiwan | NT$1.45 Billion |
|
Siamgas and Petrochemicals Public Company Limited
BK:SGP
|
Thailand | ฿37.32 Billion |
|
AROAF
PINK:AROAF
|
USA | $14.35 Million |
|
Namsun Alumini
KO:008350
|
Korea | ₩144.33 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down DIAMOND BIOFUND INC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 46.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DIAMOND BIOFUND INC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DIAMOND BIOFUND INC (2019–2024)
The table below shows the annual total liabilities of DIAMOND BIOFUND INC from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$301.55 Million | +67.77% |
| 2023-12-31 | NT$179.74 Million | +24.77% |
| 2022-12-31 | NT$144.06 Million | -37.59% |
| 2021-12-31 | NT$230.82 Million | +28.12% |
| 2020-12-31 | NT$180.16 Million | +162.35% |
| 2019-12-31 | NT$68.67 Million | -- |